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Abstract
Background: Glioblastoma (GBM), a highly aggressive brain tumor, contains a subpopulation of glioblastoma
stem-like cells (GSCs) that play roles in tumor maintenance, invasion, and therapeutic resistance. GSCs are therefore
a promising target for GBM treatment. Our group identified the cellular prion protein (PrPC) and its partner, the
co-chaperone Hsp70/90 organizing protein (HOP), as potential target candidates due to their role in GBM
tumorigenesis and in neural stem cell maintenance.
Methods: GSCs expressing different levels of PrPC were cultured as neurospheres with growth factors, and
characterized with stem cells markers and adhesion molecules markers through immunofluorescence and flow
cytometry. We than evaluated GSC self-renewal and proliferation by clonal density assays and BrdU incorporation,
respectively, in front of recombinant HOP treatment, combined or not with a HOP peptide which mimics the PrPC
binding site. Stable silencing of HOP was also performed in parental and/or PrPC-depleted cell populations, and
proliferation in vitro and tumor growth in vivo were evaluated. Migration assays were performed on laminin-1
pre-coated glass.
Results: We observed that, when GBM cells are cultured as neurospheres, they express specific stemness markers
such as CD133, CD15, Oct4, and SOX2; PrPC is upregulated compared to monolayer culture and co-localizes with
CD133. PrPC silencing downregulates the expression of molecules associated with cancer stem cells, upregulates
markers of cell differentiation and affects GSC self-renewal, pointing to a pivotal role for PrPC in the maintenance of
GSCs. Exogenous HOP treatment increases proliferation and self-renewal of GSCs in a PrPC-dependent manner
while HOP knockdown disturbs the proliferation process. In vivo, PrPC and/or HOP knockdown potently inhibits the
growth of subcutaneously implanted glioblastoma cells. In addition, disruption of the PrPC-HOP complex by a HOP
peptide, which mimics the PrPC binding site, affects GSC self-renewal and proliferation indicating that the HOP-PrPC
complex is required for GSC stemness. Furthermore, PrPC-depleted GSCs downregulate cell adhesion-related
proteins and impair cell migration indicating a putative role for PrPC in the cell surface stability of cell adhesion
molecules and GBM cell invasiveness, respectively.
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Conclusions: In conclusion, our results show that the modulation of HOP-PrPC engagement or the decrease of
PrPC and HOP expression may represent a potential therapeutic intervention in GBM, regulating glioblastoma
stem-like cell self-renewal, proliferation, and migration.
Keywords: Cellular prion protein, Hsp70/90 organizing protein, Glioblastoma, Stem cells, Proliferation,
Background
Glioblastoma (GBM) is the most common and aggres-
sive type of central nervous system (CNS) tumor and is
one of the most lethal human cancers [1]. This aggres-
sive behavior has been attributed to a highly proliferative
subset of cells called glioblastoma stem-like cells (GSCs)
that contribute to tumor initiation and therapeutic re-
sistance [2]. These cells are thought to be responsible
for maintaining GBM tumors after therapy and repopu-
lating them after total resection [3]. In addition, they are
involved in tumor angiogenesis [4] and immune evasion
[5], promoting tumor progression.
The cellular prion protein (PrPC) and the Hsp70/
Hsp90 organizing protein (HOP) modulate several stem
cell functions. PrPC regulates proliferation and self-
renewal of neural stem cells (NSCs) [6], while HOP partic-
ipates in the maintenance of pluripotent stem cells [7].
Previous data from our group show that PrPC modulates
NSC proliferation and self-renewal through its interaction
with HOP [6]. Both PrPC and HOP also modulate tumori-
genesis, affecting the progression and maintenance of dif-
ferent types of cancers [8]. PrPC associates with a poor
clinical outcome and survival in pancreatic ductal adeno-
carcinoma and melanoma [9, 10], and with invasion and
metastasis in gastric and breast cancers [8, 11, 12]. Deplet-
ing PrPC inhibits growth, promotes programmed cell
death in gliomas [13], and sensitizes tumor cells to cyto-
toxic drugs [14]. Likewise, HOP expression correlates with
tumor progression [15], and is associated with prolifera-
tion [16, 17], invasion [17], and poor patient prognosis
[18], and HOP has been described as an important regula-
tor of tumor maintenance [19–21]. Recent findings show
that HOP-PrPC binding modulates migration and invasion
of colorectal cancer cells [22]. Erlich et al. [16] reported
that the interaction of PrPC with HOP modulates prolifer-
ation in glioma cell lines, and data from our group showed
that higher expression of both proteins is correlated with
greater tumor proliferation and lower survival in patients
with GBM [15]. In addition, blocking the HOP-PrPC
complex decreases tumor growth and increases sur-
vival in an animal model [15], making it a potential
target for GBM therapy.
While the HOP-PrPC complex participates both in GBM
tumorigenesis and in the maintenance of NSCs—which are
believed to originate GSCs—their role in GSC biology is
still unclear. Therefore, this study aimed to elucidate the
role of the HOP-PrPC complex in the regulation of GSCs
by downregulating the expression of PrPC in a human
GBM cell line cultured as GSCs and by testing how prolif-
eration and self-renewal properties were affected in the
presence of exogenous HOP; we also wished to evaluate
the therapeutic potential of targeting this complex using
synthetic peptides in attempt to alter GSC biology. Add-
itionally, we investigated whether PrPC may be used as a
novel biomarker for GBM by studying its role in GSC
stemness.
Methods
Proteins and peptides
Mouse recombinant HOP was purified as previously de-
scribed [23]. Human pepHOP230–245 (ELGNDAYKKKDFD
TAL) and C-terminal pepHOP422–437 (GCKTVDLKPDW
GKGYS) peptides were synthesized by GenScript (Piscataway,
NJ, USA).
Cell culture
The human U87 and U251 glioblastoma cell lines (ATCC)
were cultured in DMEM-F12, supplemented with B27 (Cat
No. 17504-044; Gibco, Gaithersburg, MD, USA; 1:50) in
the presence of 20 ng/ml epidermal growth factor (EGF;
Cat No. E4127; Sigma Aldrich, St. Louis, MO, USA) and
basic fibroblast growth factor (bFGF; Cat No. F0291; Sigma
Aldrich) at 37 °C under 5% CO2 to form neurospheres.
The medium was replaced every 2 days. After 1 week, cells
were treated with 0.25% trypsin (Cat No. 25200-056;
Gibco) in HBSS (Cat No. 14170-112; Gibco) for 5 min at
37 °C. Trypsin was washed out and the cells were mechan-
ically dissociated and plated for distinct assays.
PrPC/HOP silencing
U87 cells were infected with lentiviral particles carrying
two constructions targeted to the human PrPC sequence
[15]. Efficiency was low for shRNA-PrP1 and high for
shRNA-PrP2. Therefore, shRNA-PrP1 was used to silence
PrPC to intermediary levels, while shRNA-PrP2 was used
for low PrPC expression. Replication-deficient lentiviral
particles were produced in HEK293FT cells using the
ViraPower Lentiviral Expressing System (Invitrogen)
according to the manufacturer’s instructions. Dr.
Andrew Hill (La Trobe University, Australia) kindly
provided the constructs for shRNA-PrPC sequences.
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The following pLenti constructs were used for the
shRNA-PrPC sequence:
shRNA-PrP1: 5′-caccgcgtcaatatcacaatcaagccgaagcttgat
tgtgatattgacgc-3′
shRNA-PrP2: 5′- caccagaacaacttcgtgcacgactcgaaaagtc
gtgcacgaagttgttc-3′
Stable silencing of HOP was performed using MISSION®
shRNA (Sigma Aldrich) according to the manufacturer’s
instructions using the following sequences: TRC 2.0;
NM_006819 – Mission – SIGMA/TRCN0000243096 and
TRCN0000243099.
CRISPR/Cas9 for PrPC knockout
The human PrPC gene sequence (NM_000311.3) was
used to design the guide RNA using the Optimized
CRISPR Design (http://crispr.mit.edu/). gRNA sequences
selected were: Hu PrPC (Top1) CACCGgctgggggcagccg
atacccg/Hu PrPC (Bottom1) AAACcgggtatcggctgccccca
gcC. The gRNAs were phosphorylated, annealed, and
cloned into px330-U6-GFP vector (Addgene) according
to the Addgene website instructions. The construct
was sequenced, transfected into the U251 cell line
with lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions, and the clones were iso-
lated by serial dilution.
Flow cytometry analysis
Cells (106) were dissociated, washed twice with
phosphate-buffered saline (PBS), and incubated with anti-
PrPC [23], anti-CD133 (Cat No. 130-090-852; Miltenyi,
Auburn, CA, USA), CD15 (Cat No. FCMAB182F;
Millipore, Temecula, CA, USA), anti-E-cadherin (Cat No.
610181; BD Bioscience, San Diego, CA, USA), and anti-
integrin α6 (Cat No. ab97760; Abcam, Cambridge, UK)
antibodies, all at 1:50 dilution in 0.5% bovine serum albu-
min (BSA) in PBS for 60 min at 4 °C. After washing, sam-
ples were incubated with anti-mouse IgG Alexa-488/PE
(Cat No. A21200; Invitrogen, Carlsbad, CA, USA; 1:200)
or with anti-rabbit IgG Alexa-488/405 (Cat No. A21441;
Invitrogen; 1:200) antibodies for 60 min at 4 °C. For PrPC
internalization assays, cells were pre-incubated for 40 min
in 250 μM solution of CuSO4 in PBS plus 5% BSA at
37 °C, followed by antibody incubation. Only secondary
staining was used for the negative control. Cells were ana-
lyzed by flow cytometry for forward scatter, side scatter,
and fluorescence (FACSCanto II; BD Biosciences).
Immunoblotting assays
For the analysis of neurosphere protein extracts, cells
were cultured overnight (2 × 105 cells/well), starved for
24 h, treated with serum or recombinant HOP for
15 min, and washed with cold PBS. Protein extracts were
prepared in RIPA buffer with protease/phosphatase in-
hibitors, centrifuged (10,000 × g), and then loaded (5 μg)
onto a 10% SDS-PAGE gel, followed by immunoblotting
with polyclonal anti-HOP (1:10,000) [23], anti-phospho
Erk1/2 (Cat No. 4370S; Cell Signaling, Danvers, MA,
USA; 1:4000), anti-Erk1/2 (Cat No. 4695S; Cell Signal-
ing; 1:4000) or anti-PrPC [23]. Anti-GAPDH (Cat No.
G9545; Sigma Aldrich) or anti-actin antibodies (Cat No.
A2103; Sigma Aldrich) were used as protein loading
controls.
Immunofluorescence staining
For PrPC and Oct4 staining, whole neurospheres were
harvested, fixed in 4% paraformaldehyde, and paraffin-
embedded. For Ki67 experiments, xenografts (Balb/c
nude mice) were resected, fixed in 4% paraformaldehyde,
and paraffin-embedded. Slides with 3-μm sections were
prepared for immunofluorescence. Sections were incu-
bated in xylol at 60 °C for paraffin removal and
immersed in citrate buffer, pH 6.0, for 1 h at 96 °C for
antigen retrieval. Sections were then blocked for 1 h at
room temperature (RT) in 5% BSA in PBS and incubated
overnight at RT with anti-PrPC (1:50) [23] or anti-Oct4
(Cat No. 2840S; Cell signaling; 1:50) in 1% BSA in PBS.
After washing, slides were incubated for 1 h at RT with
anti-mouse Alexa-488 (Cat No. A21202; Invitrogen;
1:1000) or anti-rabbit Alexa-546 (Cat No. A10040; Invi-
trogen; 1:1000), and stained with TO-PRO (Cat No.
T3605; Molecular Probes, Eugene, OR, USA) for nuclei.
For other markers, whole neurospheres were harvested,
plated on coverslips previously treated with poly-L-lysine
and fixed in 4% paraformaldehyde. Coverslips were
blocked for 1 h at RT with 5% BSA plus 0.3% triton in
PBS. Coverslips were incubated overnight at RT with
anti-PrPC (1:100) and anti-HOP (1:100) [23], anti-nestin
(Cat No. N5413; Sigma Aldrich; 1:100), anti-Musashi1
(Cat No. 5663P; Cell Signaling; 1:100), anti-Sox2 (Cat
No. ab75485; Abcam; 1:100), anti-βIII tubulin (Cat
No. 5568S; Cell Signaling; 1:100), anti-β catenin (Cat
No. ab32572; Abcam; 1:100), anti-CD133 (Cat No.
MAB4399; Millipore; 1:100), anti-GFAP (Cat No. Z0334;
Dako, Cambridge, UK; 1:100) or anti-E-cadherin (Cat No.
610181; BD Bioscience; 1:100) in 1% BSA 0.1% triton in
PBS. After washing, coverslips were incubated for 1 h at
RT with anti-mouse Alexa-488 (Cat No. A21202; Invitro-
gen; 1:1000) or anti-rabbit Alexa-546 (Cat No. A10040;
Invitrogen; 1:1000), and stained with TO-PRO (Cat No.
T3605; Molecular Probes) or DAPI (Cat No. D1306; Invi-
trogen) for nuclei. Cells were imaged on a Leica TCS SP2
II laser scanning confocal system.
Cell proliferation assay
Whole neurospheres were harvested and plated on
coverslips previously treated with poly-L-lysine in DMEM-
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F12 supplemented with B27 at 37 °C. Control cells were
treated only with the growth factors (20 ng/ml) EGF (Cat
No. E4127; Sigma Aldrich) and bFGF (Cat No. F0291;
Sigma Aldrich), and for HOP treatments cells were treated
with growth factors and recombinant HOP and/or HOP
peptides (1 μM) for 24 h. Cells received a 60-μM BrdU
pulse 3 h prior to fixation in 4% paraformaldehyde. Fixed
cells were treated with HCl 2 N for 30 min, washed with
borate buffer, and permeabilized with 0.3% Triton X-100
in PBS for 15 min. Cells were blocked in 0.3% Triton
5% BSA in PBS for 1 h and stained with biotin-conju-
gated anti-BrdU (Cat No. MAB3262B; Millipore; 1:100),
Strepta-AlexaFluor-546 (Cat No. S11225; Molecular
Probes; 1:500), and DAPI (Cat No. D1306; Invitrogen;
1:500) for nuclei. Images were taken from at least four
microscopic fields (Zeiss AxioVertA1) for each duplicate
per treatment and analyzed on ImageJ software (NIH). The
percentage of BrdU-positive nuclei in the total number of
nuclei (DAPI) was calculated. HOP-silenced populations
were plated 24 h prior to performing the transfection and
proliferation assays (as described above). For colorimetric
assays, cells were treated with growth factors and recom-
binant HOP and/or HOP peptides (1 μM) for 24 h and the
Cell Proliferation ELISA BrdU kit (Cat. No. 11647229001;
Roche, Indianapolis, IN, USA) was utilized according to
the manufacturer’s instructions.
Clonal density assay
Neurospheres were treated with 0.25% trypsin (Cat No.
25200-056; Gibco) in HBSS (Cat No. 14170-112; Gibco)
for 20 min at 37 °C. Trypsin was washed out and cells
were mechanically dissociated. In each well (96-well
plate), 200 cells were plated in triplicates per condition
(control or treatment with 500nM recombinant HOP
and/or HOP peptides). Cells were treated every 48 h for
1 week. Images were acquired through light microscopy
(Zeiss PrimoVert) and the number and size of neurospheres
were evaluated and compared between conditions with the
ZEN software (Zeiss). The optimal concentration of HOP
for self-renewal or proliferation assays was chosen based on
previous experiments of dose-response curve (data not
shown) or according to previous data [6], respectively.
Migration assay
Neurospheres were plated on coverslips previously
treated with poly-L-lysine and laminin-1 (5 μg/ml) in
DMEM-F12 supplemented with B27, and the growth
factors EGF (Cat No. E4127; Sigma Aldrich) and bFGF
(Cat No. F0291; Sigma Aldrich) and 2% fetal bovine
serum (FBS; Lot No. 003/14; Vitrocell, Campinas, Spain),
and cultured for 24 h at 37 °C. Images were acquired
through light microscopy (ZeissPrimoVert) and the halo
of migration was compared to neurosphere radius to
evaluate cell migration using ZEN software (Zeiss). For
cell scratch assays, neurospheres were dissociated and
plated 0.2 × 106 per well (six-well plate), the scratch was
performed, and images were acquired at 0 h and 24 h
after the scratch. Images of three experimental replicates
were acquired using Zeiss PrimoVert microscope and
the distance of each scratch closure after 24 h was mea-
sured by comparing with the images at time 0 h using
ZEN software (Zeiss).
In vivo tumor growth
Institutional guidelines for animal welfare were followed
and the study approved by the Animal Ethics Committee
of the Institute of Biomedical Sciences/University of Sao
Paulo (book 03, page 15, protocol number 002 of 04/03/
2014). Neurospheres (1 × 106) as single cells were injected
subcutaneously into the flank of female Balb/C nude mice
(12 weeks old) in PBS. Tumor growth was measured every
2 days and euthanasia by CO2 saturation was performed
on day 10 after tumor detection. Tumors were resected
and fixed in paraformaldehyde 4%.
Statistical analysis
One-way analysis of variance (ANOVA) followed by
Tukey’s post-hoc test was used for multiple compari-
sons. A p value <0.05 was considered statistically signifi-
cant. The non-parametric Student’s t test was also used
in migration assays. Mean values represent at least three
independent data sets; error bars represent standard er-
rors of the mean (SEM).
Results
Characterization of neurosphere culture from GBM cell line
We compared the expression of several stem cell markers
in monolayer and neurosphere cultures of the U87 glio-
blastoma cell line. Neurospheres showed higher expres-
sion of the stem cells markers CD15, CD133, Oct4,
Musashi-1, and Sox2, suggesting enrichment in the num-
ber of stem-like cells and thus supporting the use of the
neurosphere-formation assay as a model to study GSCs
(Fig. 1a–d). However, U87 monolayer cultures and neuro-
spheres presented similar expression of the neural precur-
sor marker nestin (Fig. 1c).
Effect of PrPC modulation on the expression of stem-cell
markers
Due to their roles in GBM and NSCs, PrPC and HOP
were proposed to modulate essential functions in GSC
biology. To better understand these functions, an
shRNA lentivirus system was used in the U87 cell line to
silence PrPC to intermediary (shRNA-PrP1) and low
(shRNA-PrP2) levels (Fig. 1e and f). The CRISPR/Cas9
technique was used to generate PrPC knockout U251 cells
(Fig. 1g). U251 clone 2 presented clear depletion of PrPC
expression (PrPKO) and was selected to perform functional
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Fig. 1 (See legend on next page.)
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experiments (Fig. 1g and h). Both monolayer populations
(shRNA-PrP1and shRNA-PrP2), previously used in [15],
and also PrPKO were cultured as neurospheres.
Compared to monolayer cells, PrPC is upregulated in
neurospheres (Fig. 2a); therefore, the detection of its ex-
pression may indicate tumor enrichment in stem-like
populations. Additionally, the stem cells marker CD133
was co-expressed with PrPC and co-localized partially on
the plasma membrane of neurospheres (Fig. 2b), being
internalized with PrPC in the presence of copper pre-
senting a similar endocytosis profile (Fig. 2c and d), sug-
gesting that these molecules can form a functional
complex on the membrane domain.
The stem cell marker CD133 expression is decreased
in the U87 PrP2 population compared to the parental
population (Fig. 2e), and Sox2 had higher expression in
the parental population than in the PrP2 population
(Fig. 2f ). Musashi-1, on the other hand, presented differ-
ent cellular locations: nuclei for parental population and
cytoplasm for PrP2 (Fig. 2f ). No significant difference in
expression of the neural precursor marker nestin was
observed between populations (Fig. 2f ). Cellular differ-
entiation markers, such as GFAP and βIII-tubulin, were
highly expressed in PrP2 cells compared to parental neu-
rospheres after serum stimulation (Fig. 2g). These find-
ings reveal a potential role for PrPC in the regulation of
the GSC multipotent status.
The PrPC-HOP complex modulates GSC proliferation
Recently, our group described that the expression of PrPC
and HOP associates with GBM malignancy [15] and, con-
sidering that GBM contains stem cells implicated in
tumor development, we evaluated the role of the PrPC-
HOP interaction in GSC biology. We observed a clear
co-localization of PrPC and HOP on the cell surface
of neurospheres (Fig. 3a) and both proteins are highly
expressed in neurospheres (Fig. 3b). In addition, GSC
neurospheres from both parental and shRNA-PrPC
populations present equivalent endogenous (Fig. 3c and d)
and secreted (Fig. 3e and f) HOP levels, indicating that
the expression pattern of HOP is not affected by PrPC ab-
lation in GSCs.
We evaluated the effect of exogenous (recombinant)
HOP and synthetic peptides (pepHOP230–245 which
mimics the PrPC binding site, and peptide pepHOP422–437
used as the control) on the proliferation of parental, PrP1,
and PrP2 neurospheres. After 24 h of treatment, there was
a significant increase in proliferation of parental and of
PrP1 neurospheres treated with HOP, compared to PrPC
silenced cells (PrP2) (Fig. 3g). On the other hand, popula-
tions pre-treated with pepHOP230–245 were unable to pro-
liferate in the presence of HOP (Fig. 3g), suggesting that
pepHOP230–245 is able to block the PrP
C-HOP interaction
and impair GSC proliferation. Moreover, we observed that
HOP activates the Erk1/2 pathway only in neurosphere
cultures expressing high levels of PrPC (Fig. 3h and i).
PrPC-depleted cells have increased basal levels of
phospho-Erk1/2 (Fig. 3h and i), corroborating our previ-
ous data in primary cultures from PrPC knockout mice
and literature data in different cell types [24–26]. Similar
results were obtained using an additional glioblastoma cell
line (U251). As shown in Fig. 3j the positive HOP effect
upon proliferation was also abrogated by HOP230–245 pep-
tide in U251 PrPC-expressing cells, as well as being ob-
served with U87 (Fig. 3g). Neurospheres from the PrPC
knockout U251 cell line present a very low proliferation
rate when compared to parental cells (Fig. 3j). Together
these findings indicate that PrPC-HOP interaction is able
to sustain the proliferation of GSCs of distinct glioblast-
oma cell lines.
HOP silencing impairs GSC proliferation
To determine the contribution of HOP towards GSC
proliferation, we silenced HOP expression in parental
and PrP2 populations. Decreased expression of HOP
was confirmed by immunoblotting (Fig. 4a and b). The
expression of PrPC was also addressed in HOP knockdown
cells (HOPKD) and showed a slight decrease compared to
the parental population (Fig. 4c). The proliferative basal
levels were affected in both HOPKD and PrP2/HOPKD pop-
ulations (Fig. 4d); however, the treatment with recombinant
(See figure on previous page.)
Fig. 1 Characterization of glioblastoma U87 and U251 neurospheres. a Immunofluorescence for CD133 (green) in U87 cultured as monolayer plus
serum (left) or neurospheres (right). Nuclei staining (TO-PRO) shown in red. b Dot plot for CD133 expression in monolayer cultured with serum
(left) and neurospheres (right). CD133+ cells shown in red and CD133– cells in black. c Immunostaining for the stem cells markers Oct4, Musashi-1,
Sox2, and Nestin (green) in monolayer (upper) and neurospheres (lower), with nuclei staining (TO-PRO) shown in red. d Dot plot graph for CD15
expression in monolayer cultured with serum (left) and as neurospheres (right). CD15+ shown in red and CD15– in black. e Cellular prion protein
(PrPC) expression assessed by flow cytometry in parental (orange), shRNA-PrP1 (green), or shRNA-PrP2 (red) populations. Negative control shown in
blue (only secondary antibody staining). f Immunofluorescence for PrPC (green), in parental (left), shRNA-PrP1 (middle), or shRNA-PrP2 (right) populations.
Arrow indicates staining on the cell surface and arrowhead in the perinuclear region. Nuclei staining (TO-PRO) shown in red. g Immunoblot for Hsp70/
90 organizing protein (HOP) (top) and PrPC (bottom) expression in U251 knockout (PrPKO) clones (1 and 2) compared to the parental (Ptl) population.
GAPDH was used as the loading control. Note that the smear for PrPC immunostaining is due to the different glycosylated isoforms. h Flow cytometry
for PrPC expression in the U251 populations parental (left) and U251 PrP-knockout clone 2 (PrPKO) (middle). IgG isotype (right) was used as the
negative control
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HOP is able to rescue the proliferation phenotype in
PrPC-positive cells (Fig. 4d). Together, these results
indicate both PrPC and HOP as key players in the
regulation of GSC proliferation.
PrPC and HOP depletion decreases GSC tumorigenicity in
vivo
Neurosphere cells expressing different levels of PrPC
and/or HOP were injected subcutaneously into Balb/c
nude mice flanks and tumor growth was evaluated.
As depicted in Fig. 4e, cells expressing PrPC grew
rapidly, while ablated cells for PrPC (PrP2) and/or
HOP (HOPKD) showed slower or no tumor formation.
Histological sections of resected tumors showed that
PrPC or HOP silencing caused cell proliferation re-
duction, as depicted by Ki-67 nuclear immunostaining
(Fig. 4f and g). These data support our in vitro assays
and highlight the importance of PrPC and HOP in
Fig. 2 Stem cells marker expression in cellular prion protein (PrPC)-depleted neurospheres. a PrPC expression assessed by flow cytometry in parental
monolayer (red) and neurosphere (green) cultures. Negative control shown in blue (only secondary antibody staining). b Immunofluorescence for
PrPC (red) and CD133 (green) in parental neurospheres shows co-localization on the cell surface. c Dot plot of CD133 and PrPC expression in parental
neurospheres in the absence (–Cu2+) or presence (+Cu2+) of CuSO4 250 μM. d Histogram for PrPC and CD133 in the absence (–Cu2+) and presence
(+Cu2+) of CuSO4 250 μM. Negative control shown in blue (only secondary antibody staining). e Dot plot of CD133 expression in parental (left) and
shRNA-PrP2 (right) neurospheres. CD133+ shown in red and CD133– shown in black. f Immunofluorescence for the stem cells markers musashi-1, nestin,
Sox2, and CD133 (green) in parental (upper) and shRNA-PrP2 (lower) neurospheres. Nuclei staining (TO-PRO) shown in red. g Immunofluorescence for
the cell differentiation markers GFAP and βIII-tubulin (green) in parental (left) and shRNA-PrP2 (right) neurospheres after 5 days of serum treatment.
Nuclei staining (TO-PRO) shown in red
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tumor maintenance through the modulation of GSC
proliferation.
Self-renewal of GSCs depends on PrPC expression and its
interaction with HOP
Since the proposal that NSCs originate GSCs, important
data describing the induction of NSC self-renewal by
HOP-PrPC interaction has emerge, supporting a function
for PrPC and HOP in GSC biology [6]. Thus, self-renewal
was evaluated by formation of secondary neurospheres in
clonal density assays. Cells expressing lower PrPC levels
(PrP2 population) formed fewer colonies when compared
to parental and PrP1 populations (Fig. 5a). HOP increased
the number of neurospheres in parental and PrP1 popula-
tions when compared to untreated cells. However, any
HOP effect was observed in the PrP2 population that
lacked PrPC (Fig. 5a). These results indicate that PrPC ex-
pression is required for self-renewal and is also necessary
to mediate HOP activity. Neurosphere formation medi-
ated by HOP-PrPC interaction was abrogated in the pres-
ence of pepHOP230–245, which mimics and competes for
the PrPC binding site. The control peptide pepHOP422–437
(Fig. 5a) did not have any effect.
As previously described, PrPC ablation decreases neu-
rosphere number (Fig. 5a) probably by downregulating
essential molecules involved in stem cell maintenance
(Fig. 2), supporting its previously suggested role in stem-
ness. The smaller size of neurospheres formed by PrPC-
depleted cells (compared to their counterparts) suggests
a putative role for PrPC in GSC cell adhesion mainten-
ance (Fig. 5b; Additional file 1: Figure S1A). To address
this issue, the expression of E-cadherin and β-catenin,
Fig. 3 Hsp70/90 organizing protein (HOP) promotes proliferation of neurospheres dependent on cellular prion protein (PrPC) by activating the
Erk1/2 signaling pathway. Immunofluorescence for PrPC (green) and HOP (red) in parental neurospheres shows co-localization on the cell surface
in non-permeabilized cells (a) and expression of both proteins in the cytoplasm in permeabilized cells (b). Nuclei staining (TO-PRO) in shown in blue. A
higher magnification field is shown in the inset. c Immunoblot for HOP in parental (Ptl), shRNA-PrP1 (PrP1), and shRNA-PrP2 (PrP2) neurospheres.
GAPDH was used as the loading control. d Densitometry analysis of immunoblot; values of three independent experiments are expressed relative to
control (parental). e Immunoblot of conditioned medium of parental (Ptl), shRNA-PrP1 (PrP1), and shRNA-PrP2 (PrP2) PrPC-depleted populations. Total
protein extract (Ext). GAPDH immunodetection was used as cell lysis control. f Densitometry analysis of immunoblot; values of three independent
experiments are expressed relative to control (parental). g U87 neurospheres treated with HOP and/or peptides pepHOP230–245 or pepHOP422–437
(1 μM), combined or alone, compared to untreated control. Percentage of BrdU-positive cells in all conditions in relation to total number of cells
(n = 6, *p < 0.005). h Immunoblot of phosphorylated Erk1/2 and total Erk1/2 in parental and shRNA-PrP2 neurospheres for basal levels (Ctrl), fetal bovine
serum (FBS), or recombinant HOP treatments (HOP) for 20 min. GAPDH was used as the loading control. i Densitometry of the relative values of ERK1/2
activation are represented by the ratio of p-ERK and total ERK1/2 in parental and shRNA-PrP2 neurospheres after treatment with recombinant HOP or
FBS. j U251 neurospheres of parental and U251 knockout (PrPKO) populations treated with HOP and/or peptides pepHOP230–245 or pepHOP422–437
(1 μM), combined or alone, compared to untreated control. BrdU-positive cells detected by spectrophotometry (n = 4, p < 0.05, ANOVA followed by
Tukey post-hoc test)
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key components of adherens junctions, was evaluated in
PrP2 neurospheres and parental control populations.
The expression of E-cadherin is associated with PrPC on
the cell surface; this was more obvious for the parental
population, where there was higher expression of E-
cadherin (Fig. 5c) and a clear double staining for both
proteins in neurosphere cells (Fig. 5d). Although the cell
membrane of parental cells had high E-cadherin expres-
sion, PrP2 had abundant cytoplasmic E-cadherin (Fig. 5e).
Parental and PrP2 neurospheres expressed β-catenin
abundantly at similar levels. However, there was an in-
tense co-localization of β-catenin and PrPC in the same
membrane domain of parental neurospheres, while in
PrP2 neurospheres the β-catenin expression was diffuse
(Fig. 5f). This may suggests that PrPC plays a role in E-
cadherin recruitment to the cell membrane and, conse-
quently, on β-catenin engagement.
Due to its putative function as a scaffold protein and
multiprotein assembly platform on the cell surface, we
also tested if additional anchorage-dependent cell pro-
cesses, such as migration, was altered in PrPC-depleted
cells. Additionally, migration on laminin is impaired in
PrPC-silenced cells compared to parental neurospheres
(Fig. 5g and h; Additional file 1: Figure S1B). Moreover,
the surface expression of integrin α6β1, a laminin recep-
tor, was verified. Integrin α6 expression is clearly more
evident in parental neurospheres compared to PrP2
(Fig. 5i) and is co-expressed with PrPC, while integrin β1
expression is apparently similar in both populations
(Fig. 5j). However, a high co-localization of integrin
β1 and PrPC was observed (Fig. 5k), suggesting that
PrPC plays a key function in enhancing cell surface
stability of cell adhesion molecules, thereby modulat-
ing the invasive process.
Discussion
In this study, the role of the PrPC-HOP complex in the
regulation of GSC biology was evaluated. First, we dem-
onstrated that our model of neurospheres expressed sev-
eral markers of stemness. The expression of CD15,
CD133, Oct4, Musashi-1, and Sox2 was increased in
neurospheres compared to a non-stem condition (mono-
layer), validating our experimental model (Fig. 1). PrPC
expression was higher in neurospheres than in mono-
layer cultures (Fig. 2a) and, since the enrichment of
GBM cultures with stem cells leads to more malignant
tumors in vivo [27], these data support previous results
from our group which show that PrPC expression is cor-
related with tumor aggressiveness [6, 15].
PrPC expression seems to be associated with stem-like
properties, since its silencing led to a differentiated ex-
pression of stem cell markers. Compared to parental
neurospheres, CD133 expression decreased and Sox2 ex-
pression became undetectable in PrPC-depleted popula-
tions (Fig. 2e and f). Previous studies have shown that
CD133 and Sox2 are exclusively expressed at perinecrotic
and perivascular regions associated with stem-like cell
pools, and that nestin and Musashi-1 are homogeneously
Fig. 4 Cellular prion protein (PrPC) and/or Hsp70/90 organizing protein (HOP) knockdown suppresses cell proliferation and tumor growth in vivo.
a Immunoblot for HOP expression in U87 non-target (NT), shRNA-HOP (HOPKD), or shRNA-PrP2/HOP (PrP2/HOPKD) populations. Actin was used as
the protein loading control. b Immunoblot densitometry analysis; values of three independent experiments are expressed relative to control
(parental). c Dot plot for PrPC expression of U87 parental and HOPKD populations. PrPC+ cells shown in red and PrPC– cells shown in black. d. Colorimetric
BrdU incorporation assay in U87 parental, HOPKD, PrP2, or PrP2/HOPKD populations. Values of four independent experiments are expressed relative to
control (parental). *p < 0.05, ANOVA followed by Tukey post-hoc test. e U87 neurospheres cells from parental, PrP2, HOPKD, or PrP2/HOPKD populations
(1 × 106 cells) were implanted into the flank of nude mice and the tumor growth was monitored daily. Data represent tumor volume on day 10 after
tumor detection (n= 4, *p < 0.05, ANOVA followed by Tukey post-hoc test). f Tumors were resected, fixed, paraffin embedded, and immunostained for
Ki67. Representative images of Ki67 labeling (red) and DAPI (nuclei, blue). g Values represent the percentage of Ki67-positive cells relative to total number
of cells (nuclei, DAPI staining)
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Fig. 5 Cellular prion protein (PrPC) promotes GSC self-renewal binding HOP and modulates cell surface adhesion molecule stability. Neurosphere
number (a) or size (b) after 1 week treatment every 48 h with Hsp70/90 organizing protein (HOP) and peptides pepHOP230–245 and pepHOP422–437
(1 μM), combined or alone (500nM), compared to control (n = 6, *p < 0.05, ANOVA followed by Tukey post-hoc test). c Dot plot of E-cadherin expression
in parental and shRNA-PrP2 neurospheres. E-cad+ cells shown in red and E-cad– cells shown in black. d Dot plot of E-cadherin and PrPC expression in
parental and shRNA-PrP2 neurospheres. e Immunofluorescence for E-cadherin (green) in parental and shRNA-PrP2 neurospheres, showing expression
on the cell surface (parental) and in the perinuclear region (shRNA-PrP2). Nuclei (TO-Pro) stain shown in red. f PrPC (green) and β-catenin (red) expression
and co-localization (yellow) of parental and shRNA-PrP2 neurospheres. g Migration assay, ratio between cell migration distance (halo), and neurosphere
size for parental and shRNA-PrP2 neurospheres 24 h after plating on laminin-1 (n = 3, *p < 0.05). h Cell scratch assay; images of three experimental
replicates were acquired and the distance of each scratch closure after 24 h was measured by comparing with the images at time 0 h for parental and
shRNA-PrP2 neurospheres plated on laminin-1 (n = 4, *p < 0.05). i Dot plot of α6 integrin and PrPC expression in parental and shRNA-PrP2 neurospheres.
j Immunofluorescence for β1 integrin (green) of parental and shRNA-PrP2 neurospheres. Nuclei (TO-PRO) stain shown in red. k. PrPC (green) and β1
integrin (red) expression and co-localization (yellow) of parental and shRNA-PrP2 neurospheres. Nuclei (TO-PRO) stain shown in blue; a higher
magnification is shown in the inset
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expressed across the tumor, identifying precursors [28].
PrP2 neurospheres expressed Musashi-1 in the cytoplasm
in contrast to parental neurospheres, where it segregated
preferentially to cell nuclei (Fig. 2f). Nuclear expression of
Musashi-1 has been associated with activation of the
Notch pathway in gliomas [29, 30] which, in turn, may
lead to increased tumor malignancy via induction of pro-
liferation and therapy resistance [31]. The expression of
nestin was similar in parental and PrP2 neurospheres
(Fig. 2f). Expression of differentiation markers is more evi-
dent in PrP2 neurospheres compared to the parental
population after serum stimuli (Fig. 2g). Together, our re-
sults suggest that parental neurospheres have a stem-like
phenotype with some precursor cells, and that the PrP2
population has precursors and cells committed to a spe-
cific phenotype. Indeed, the function of PrPC in stem cell
biology has been broadly studied. PrPC has been described
as an important molecule for neural commitment and for
the proliferation of precursors [32]. In tumor stem-like
cells, PrPC promotes proliferation and migration [11].
PrPC interacts with the cell surface protein CD44, a
marker for several types of cancer stem-like cells [33] that
associates with tumor-initiating and metastatic capacities
and promotes epithelial-mesenchymal transition (EMT)
and tumor growth after resection [34].
A possible interaction between PrPC and CD133 was
also observed given their co-expression and localization on
the cell surface of parental neurospheres (Fig. 2b and c).
PrPC and CD133 were previously shown to localize to the
same membrane domains (lipid rafts), modulating differen-
tiation and stemness, respectively [35]. Additionally, a re-
duction in cell surface expression of CD133 associated
with PrPC was observed after copper stimulus, suggesting
PrPC as a carrier for CD133 internalization (Fig. 2c and d).
PrPC is constitutively endocytosed via clatrin-coated pits
[36] and copper ions reversibly stimulate this endocytic
pathway [37]. CD133 has been shown to affect the
clathrin-endocytosis process [38] and trafficking down the
endosomal and lysosomal pathway for degradation [39].
Remarkably, the cytoplasmatic domain of CD133 binds β-
catenin and the downregulation of CD133 increases β-
catenin degradation and impairs tumor growth in vitro and
in vivo [39]. Indeed, the β-catenin localization was per-
turbed in PrPC-depleted cells (Fig. 5f), suggesting the cen-
tral role of PrPC in the stabilization of the signaling
module on the cell surface.
PrPC-depleted populations formed less secondary neu-
rospheres (Fig. 5a), suggesting that withdrawing PrPC
impairs self-renewal ability. This supports the hypothesis
that PrPC can act as an important player in stemness
maintenance and that its dowregulation induces cell line
commitment, corroborating recent evidence that showed
a less oncogenic phenotype in PrPC-depleted GSCs [40].
Thus, it is possible that PrPC acts as an essential molecule
for GSC biology and is capable of maintaining an undiffer-
entiated state in this GBM subpopulation and, since
its expression may indicate tumor enrichment with
stem-like cells, it may be used as a tumor progression
marker. Interesting, the effect of temozolomide, a com-
mon chemotherapeutic agent for brain tumors, is en-
hanced in PrPC-depleted glioma cells, supporting PrPC as
an effective target for GBM [41].
As a number of studies show that PrPC acts as a scaf-
fold protein, assembling signaling platforms on the
plasma membrane to elicit several biological processes
including in stem cells (reviewed in [8, 42]), we looked
for alterations in the expression of cell adhesion proteins
on the cell surface of GSCs. We observed a decrease in
E-cadherin and integrin α6 expression on the cell sur-
face of PrPC-silenced populations (Fig. 5c, d and i), and
detected E-cadherin in the cytoplasm (Fig. 5e). The ex-
pression of these proteins was also associated with PrPC,
as E-cadherin- or integrin α6-positive cells were almost
exclusively positive for PrPC (Fig. 5d and i). Integrin β1
expression was detected in both parental and PrP2 neu-
rospheres, and co-localized with PrPC on the cell surface
(Fig. 5j and k). In addition, GSC migration on laminin
was impaired in PrPC-depleted cells (Fig. 5g and h). In-
deed, it has been demonstrated that PrPC participates in
E-cadherin recruitment to the cell surface [43] with
no significant differences verified in transcripts levels
[43, 44]. Interestingly, it was demonstrated that PrPC-
null mice present increased paracellular permeability, with
lower levels of E-cadherin, desmoplakin, occluding, and
other proteins related to cell-cell junctions in intestinal
tissues [45]. Furthermore, it was reported that PrPC is able
to regulate β1 integrin adhesiveness modulating ligand-
induced changes in integrin activation [46]; however, its
depletion had no effect on total β1 integrin expression
levels [47]. These data suggest that PrPC may be capable
of recruiting cell adhesion molecules to the cell surface of
GSCs, raising the hypothesis of PrPC modulating
invasion-related processes.
We also reported that GSCs have high expression of
HOP and PrPC (Fig. 3b) and described the HOP-PrPC
engagement on their plasma membrane (Fig. 3a). HOP
expression and secretion was similar in parental, PrP1,
and PrP2 populations (Fig. 3c–f ), as demonstrated previ-
ously by Santos and collaborators in murine wild-type
and PrPC-null neurospheres [6]. We demonstrated that
HOP is able to modulate GSC proliferation (Fig. 4d) and
self-renewal, depending on its interaction with PrPC
(Figs. 3g, 4d, and 5a); inhibiting the PrPC-HOP inter-
action with a HOP peptide, which mimics the PrPC
binding site, abrogates the effects of recombinant HOP
(Figs. 3g and 5a). Similar effects were also observed in
another glioblastoma cell line (U251) confirming the im-
portance of these complexes in GSC biology (Fig. 3j).
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Another HOP peptide (anti-TPR), which inhibits the
HOP-Hsp90 interaction, has been described to induce
cell death in several cancer cell lines [48] and produce a
cytotoxic effect in glioblastomas [49], highlighting HOP
as a potential target for GBM therapy. Previous reports
[15] as well as data from this study (Fig. 3e and h) also
described that PrPC and secreted HOP interact on the
cell surface of human glioblastoma cell lines and modulate
GBM progression by promoting proliferation through ac-
tivation of the Erk1/2 pathway [16]. Remarkably, a higher
basal phosphorylation of Erk was found in PrPC-depleted
cells when compared to their counterparts (Fig. 3h and i),
confirming our prior data in retinae [24] and hippocampal
neurons [25], as well as those from other authors in adult
brain and cerebellum extracts [26]. This feature suggests
that high activity of Erk could be a compensatory effect
for prion protein ablation [42]. Indeed, the targeting of
stress response proteins has remarkable potential for the
development of molecular treatments. Simultaneous in-
hibition of expression of both HOP ligands Hsp70 and
Hsp90 reduced proliferation and promoted apoptosis in
GBM cell lines in vitro [50]. Furthermore, HOP performs
an important function in compensatory mechanisms of
stress responses in tumor cells [51], further supporting its
relevance in GBM maintenance.
Finally, we observed that PrPC and/or HOP knock-
down affects the proliferative and tumorigenic capacity
of GSCs (Fig. 4e and f) in vivo, and supports PrPC and
HOP molecules as potential new targets for developing
more efficient therapeutic strategies.
Conclusions
Here, we reported that HOP promotes GSC proliferation
and self-renewal by interacting with PrPC and that silen-
cing PrPC significantly impairs GSC self-renewal. PrPC-
silenced cells have lower expression of stem cell markers
and increased differentiation, suggesting that PrPC plays
a role in maintenance of an undifferentiated state in
GSCs. HOP and PrPC ablation suppresses the malig-
nancy of GBM cells in vivo and has potential application
as a therapeutic target in glioblastoma. In addition, PrPC
could play a role in the expression and cell surface
localization of cell adhesion proteins, participating in cell
migration mechanisms and, consequently, in invasion.
Our results suggest that one mechanism by which PrPC
governs GSC biology is through its role as a cell surface
scaffold protein assembling a dynamic signaling platform
and also interacting with soluble partners, such as HOP,
to maintain stemness status (Fig. 6).
Major commitments for developing novel therapeutic
strategies for GBM are under way, as this is an ex-
tremely aggressive type of cancer. In particular, several
attempts to therapeutically eradicate GSCs have been
made, as these cells have well-established characteristics
in tumors. Our findings support the concept that PrPC,
HOP, and their complex are important for GSC biology,
Fig. 6 Model of prion protein (PrP) as a scaffold protein modulating GSC biology. Scheme illustrating how PrPC may act as a scaffold protein,
regulating stemness (dowregulation of CD133 and Sox2 and Msi1 sub-localization altered), recruiting cell adhesion molecules (E-cadherin and
integrin α6β1), binding CD133-β-catenin to the plasma membrane, and modulating GSC proliferation and self-renewal through its interaction with
Hsp70/90 organizing protein (HOP). Blockage of PrPC-HOP interaction with HOP peptide impairs the binding of HOP and PrPC and, consequently,
Erk1/2 activation, affecting proliferation
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regulating essential mechanisms for tumor maintenance.
Therefore, they represent a novel target for developing
new treatments for GBM or for improving the efficacy
of current therapies by targeting GSCs.
Additional file
Additional file 1: Figure S1. Representative images of self-renewal and
migration assays. (A) Representative image of self-renewal assay. Left panel:
neurosphere growth in parental, shRNA-PrP1 (PrP1), and shRNA-PrP2 (PrP2)
populations. Right panel: neurosphere size for the parental population
untreated control (Ctrl) and cells treated with recombinant HOP (HOP).
(B) Representative images of the migration assay of Parental (left) and
shRNA-PrP2 (right) neurospheres 24 h after plating on laminin-1 (n = 4,
*p < 0.05). (PPTX 205 kb)
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